Your session is about to expire
← Back to Search
Biological
Plasma Injections for Knee Osteoarthritis (A2MRP Trial)
Phase 1 & 2
Waitlist Available
Led By Brennan Boettcher, D.O
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
No Placebo-Only Group
Summary
This trial aims to see if injections of a person's own plasma rich in alpha-2 macroglobulin can help with knee osteoarthritis.
Who is the study for?
This trial is for adults aged 18-65 with moderate knee osteoarthritis, experiencing pain greater than 4 on a scale of 0-10. Participants must have tried conservative treatments for over six weeks and be fluent in English. Excluded are pregnant individuals, those with recent infections or surgeries in the target knee, BMI over 35, significant knee deformity or alignment issues, chronic immunosuppression, or current tobacco/nicotine use.
What is being tested?
The study tests the safety and effectiveness of A2MRP injections directly into the knee to treat symptoms of osteoarthritis. It aims to see if this treatment can reduce pain and improve joint function compared to standard therapies.
What are the potential side effects?
Potential side effects may include reactions at the injection site such as pain, swelling or infection; however specific side effects related to A2MRP are not detailed but will be monitored throughout the study.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Adverse Events
Secondary study objectives
Knee Injury and Osteoarthritis Outcome Score (KOOS)
Patient-Reported Outcomes Measurement Information System (PROMIS)-Computer adaptive test (CAT): Pain interference
Patient-Reported Outcomes Measurement Information System (PROMIS)-Computer adaptive test (CAT): Physical function
+2 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Autologous Alpha-2 Macroglobulin Rich Plasma (A2MRP)Experimental Treatment1 Intervention
Autologous Alpha-2 Macroglobulin Rich Plasma (A2MRP) is produced by filtering Platelet Poor Plasma (PPP), a Platelet Rich Plasma byproduct, through a hemoconcentrator filter. (PPP) is frequently used in clinical practice to increase volume of PRP or Bone Marror Aspirate Concentrate (BMAC) injectate, and it is occasionally injected in isolation for some indication
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Mayo ClinicLead Sponsor
3,362 Previous Clinical Trials
3,066,104 Total Patients Enrolled
31 Trials studying Osteoarthritis
3,071 Patients Enrolled for Osteoarthritis
Brennan Boettcher, D.OPrincipal InvestigatorMayo Clinic